柳药集团 (603368.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

8.2x

Market Cap

CNY 6.25B

MomentumView details →

1D Return

−0.88%

YTD Return

−12.01%

RSI (14)

46.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

8.2x

Market Cap

CNY 6.25B

RSI (14)

46.0

MomentumView details →

1D Return

−0.88%

YTD Return

−12.01%

ProfitabilityView details →

Gross Margin

10.93%

Net Margin

3.13%

EBITDA Margin

4.79%

ROE (TTM)

8.20%

ROA (TTM)

3.15%

Asset Turnover

1.00x

GrowthView details →

Revenue YoY

+1.26%

EPS YoY

−19.72%

FCF YoY

+31.50%

Revenue CAGR 3Y

+3.18%

EPS CAGR 3Y

−2.65%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.36

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

−1.06%

Capital & dividendView details →

Debt/Equity

0.50x

Current Ratio

1.60x

Quick Ratio

1.30x

Div Yield

4.34%

Div Rate

CNY 0.68

Div Growth 1Y

−9.45%

Financials snapshotView financials →

Revenue (TTM)

20.99B

Net Income (TTM)

656.72M

Op. CF (TTM)

1.09B

Next earningsOct 22, 2026 →

Latest newsMore news →

Liuzhou Pharmaceutical Group announced its first-half 2026 results: revenue of 10.526 billion yuan, up 2.19% year-on-year, and net profit attributable to shareholders of 369 million yuan, down 14.00% year-on-year.3d ago

Similar companies

南京医药600713.SH Medlive Technology Co., Ltd.02192.HK Henry Schein, Inc.HSIC 160 Health International Ltd.02656.HK 中国医药600056.SH Guardian Pharmacy Services, Inc.GRDN Find similar companies →

Latest newsMore news →

Liuzhou Pharmaceutical Group announced its first-half 2026 results: revenue of 10.526 billion yuan, up 2.19% year-on-year, and net profit attributable to shareholders of 369 million yuan, down 14.00% year-on-year.3d ago